vs
APOGEE ENTERPRISES, INC.（APOG）とPacira BioSciences, Inc.（PCRX）の財務データ比較。上の社名をクリックして会社を切り替えられます
APOGEE ENTERPRISES, INC.の直近四半期売上が大きい（$351.4M vs $177.4M、Pacira BioSciences, Inc.の約2.0倍）。APOGEE ENTERPRISES, INC.の純利益率が高く（4.7% vs 1.6%、差は3.1%）。Pacira BioSciences, Inc.の前年同期比売上増加率が高い（5.0% vs 1.6%）。過去8四半期でAPOGEE ENTERPRISES, INC.の売上複合成長率が高い（2.9% vs -0.2%）
Apogee Enterprisesはアメリカのオーディオ機器メーカーです。オーディオインターフェース、AD/DAコンバーター、USB・iOS対応マイクの製造を主軸に、オーディオ制作向けソフトウェアの開発も手がけており、プロの録音や音楽制作分野で広く利用されています。
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
APOG vs PCRX — 直接比較
損益計算書 — Q4 FY2026 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $351.4M | $177.4M |
| 純利益 | $16.6M | $2.9M |
| 粗利率 | 22.4% | — |
| 営業利益率 | 7.3% | 3.9% |
| 純利益率 | 4.7% | 1.6% |
| 売上前年比 | 1.6% | 5.0% |
| 純利益前年比 | 568.8% | — |
| EPS（希薄化後） | $0.78 | $0.07 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $351.4M | $177.4M | ||
| Q4 25 | $348.6M | $196.9M | ||
| Q3 25 | $358.2M | $179.5M | ||
| Q2 25 | $346.6M | $181.1M | ||
| Q1 25 | $345.7M | $168.9M | ||
| Q4 24 | $341.3M | $187.3M | ||
| Q3 24 | $342.4M | $168.6M | ||
| Q2 24 | $331.5M | $178.0M |
| Q1 26 | $16.6M | $2.9M | ||
| Q4 25 | $16.5M | — | ||
| Q3 25 | $23.6M | $5.4M | ||
| Q2 25 | $-2.7M | $-4.8M | ||
| Q1 25 | $2.5M | $4.8M | ||
| Q4 24 | $21.0M | — | ||
| Q3 24 | $30.6M | $-143.5M | ||
| Q2 24 | $31.0M | $18.9M |
| Q1 26 | 22.4% | — | ||
| Q4 25 | 23.8% | 79.5% | ||
| Q3 25 | 23.1% | 80.9% | ||
| Q2 25 | 21.7% | 77.4% | ||
| Q1 25 | 21.6% | 79.7% | ||
| Q4 24 | 26.1% | 78.7% | ||
| Q3 24 | 28.4% | 76.9% | ||
| Q2 24 | 29.8% | 75.1% |
| Q1 26 | 7.3% | 3.9% | ||
| Q4 25 | 7.1% | 1.2% | ||
| Q3 25 | 7.5% | 3.5% | ||
| Q2 25 | 2.0% | 4.7% | ||
| Q1 25 | 1.8% | 1.2% | ||
| Q4 24 | 8.4% | 13.2% | ||
| Q3 24 | 12.3% | -82.8% | ||
| Q2 24 | 12.5% | 15.9% |
| Q1 26 | 4.7% | 1.6% | ||
| Q4 25 | 4.7% | — | ||
| Q3 25 | 6.6% | 3.0% | ||
| Q2 25 | -0.8% | -2.7% | ||
| Q1 25 | 0.7% | 2.8% | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 8.9% | -85.1% | ||
| Q2 24 | 9.4% | 10.6% |
| Q1 26 | $0.78 | $0.07 | ||
| Q4 25 | $0.77 | $0.05 | ||
| Q3 25 | $1.10 | $0.12 | ||
| Q2 25 | $-0.13 | $-0.11 | ||
| Q1 25 | $0.12 | $0.10 | ||
| Q4 24 | $0.96 | $0.38 | ||
| Q3 24 | $1.40 | $-3.11 | ||
| Q2 24 | $1.41 | $0.39 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $39.5M | $144.3M |
| 総負債低いほど良い | $232.3M | — |
| 株主資本純資産 | $511.8M | $653.9M |
| 総資産 | $1.1B | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.45× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $39.5M | $144.3M | ||
| Q4 25 | $41.3M | $238.4M | ||
| Q3 25 | $39.5M | $246.3M | ||
| Q2 25 | $32.8M | $445.9M | ||
| Q1 25 | $41.4M | $493.6M | ||
| Q4 24 | $43.9M | $484.6M | ||
| Q3 24 | $51.0M | $453.8M | ||
| Q2 24 | $30.4M | $404.2M |
| Q1 26 | $232.3M | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | $285.0M | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $511.8M | $653.9M | ||
| Q4 25 | $512.3M | $693.1M | ||
| Q3 25 | $500.2M | $727.2M | ||
| Q2 25 | $481.8M | $757.8M | ||
| Q1 25 | $487.9M | $798.5M | ||
| Q4 24 | $522.1M | $778.3M | ||
| Q3 24 | $506.4M | $749.6M | ||
| Q2 24 | $480.0M | $879.3M |
| Q1 26 | $1.1B | $1.2B | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $917.1M | $1.5B | ||
| Q2 24 | $889.0M | $1.6B |
| Q1 26 | 0.45× | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | 0.58× | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $122.5M | — |
| フリーキャッシュフロー営業CF - 設備投資 | — | — |
| FCFマージンFCF / 売上 | — | — |
| 設備投資強度設備投資 / 売上 | 7.8% | — |
| キャッシュ転換率営業CF / 純利益 | 7.37× | — |
| 直近12ヶ月FCF直近4四半期 | — | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $122.5M | — | ||
| Q4 25 | $29.3M | $43.7M | ||
| Q3 25 | $57.1M | $60.8M | ||
| Q2 25 | $-19.8M | $12.0M | ||
| Q1 25 | $30.0M | $35.5M | ||
| Q4 24 | $31.0M | $33.1M | ||
| Q3 24 | $58.7M | $53.9M | ||
| Q2 24 | $5.5M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $22.9M | $43.5M | ||
| Q3 25 | $52.4M | $57.0M | ||
| Q2 25 | $-26.9M | $9.3M | ||
| Q1 25 | $19.1M | $26.9M | ||
| Q4 24 | $22.0M | $31.0M | ||
| Q3 24 | $50.2M | $49.8M | ||
| Q2 24 | $-1.8M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 22.1% | ||
| Q3 25 | 14.6% | 31.7% | ||
| Q2 25 | -7.8% | 5.1% | ||
| Q1 25 | 5.5% | 15.9% | ||
| Q4 24 | 6.4% | 16.6% | ||
| Q3 24 | 14.7% | 29.6% | ||
| Q2 24 | -0.5% | 29.0% |
| Q1 26 | 7.8% | — | ||
| Q4 25 | 1.9% | 0.1% | ||
| Q3 25 | 1.3% | 2.2% | ||
| Q2 25 | 2.1% | 1.5% | ||
| Q1 25 | 3.2% | 5.1% | ||
| Q4 24 | 2.6% | 1.1% | ||
| Q3 24 | 2.5% | 2.4% | ||
| Q2 24 | 2.2% | 0.9% |
| Q1 26 | 7.37× | — | ||
| Q4 25 | 1.77× | — | ||
| Q3 25 | 2.41× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | 12.08× | 7.37× | ||
| Q4 24 | 1.48× | — | ||
| Q3 24 | 1.92× | — | ||
| Q2 24 | 0.18× | 2.82× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
